Document is current

Article History

Received: 21 July 2022

Revised: 8 November 2022

Accepted: 8 November 2022

First Online: 18 November 2022

Declarations

:

: KK reports honoraria from Kyowa Kirin, MSD, Chugai, Novartis, and Takeda; research funds from Celgene, Chugai, Daiichi Sankyo, Ono, Eisai, Janssen, AbbVie, Kyowa Kirin, Takeda, and Novartis; and scholarship donations from Mundipharma. N. Fujii reports honoraria from Celgene, Daiichi Sankyo, Janssen, and Novartis. SM is an advisor for Celgene/BMS and Takeda and reports honoraria from Celgene/BMS, Chugai, CSL Behring, Daiichi Sankyo, Eisai, Novartis, SymBio, and Takeda. HG is an advisor or consultant for Celgene/BMS, Chugai, Daiichi Sankyo, and Novartis and reports honoraria from Celgene/BMS, Chugai, Daiichi Sankyo, Eisai, Janssen, Kyowa Kirin, Novartis, SymBio, MSD, and Takeda and research funds from Celgene/BMS. JK is an advisor for Daiichi Sankyo, Janssen, and Novartis and reports honoraria from Janssen, Takeda, Novartis, Sumitomo Dainippon, Daiichi Sankyo, Sanofi, Astellas, Amgen, Bristol-Myers Squibb, Chugai, and Ono and research funding from Eisai. KS reports honoraria from AstraZeneca, Eisai, Celgene, Takeda, Janssen, Bristol-Myers Squibb, Chugai, Kyowa Kirin, Nippon Shinyaku, Daiichi Sankyo, AbbVie, CSL Behring, Novartis, and SymBio and grants from Eisai, Celgene, Otsuka, MSD, Chugai, and Kyowa Kirin. KA reports honoraria from Astellas, AstraZeneca, AbbVie, Bayer, Bristol-Myers Squibb, Celgene, Chugai, Daiichi Sankyo, Eisai, Janssen, Japan Blood Products Organization, Kyowa Kirin, Mochida, Nippon Shinyaku, Novartis, Ono, Pfizer, Sanofi, Shionogi, Sumitomo Dainippon, SymBio, and Takeda and grants and/or research funds from AbbVie, Asahi Kasei, Astellas, Bristol-Myers Squibb, Chugai, Eisai, Japan Blood Products Organization, Kyowa Kirin, Otsuka, Nippon Shinyaku, Sumitomo Dainippon, Shionogi, Taiho, and Takeda. KI reports honoraria from Celgene, Novartis, Daiichi Sankyo, Janssen, Ono and Chugai and research funds from AstraZeneca, AbbVie, Incyte, Celgene, Bristol-Myers Squibb, Novartis, Bayer, Pfizer, Janssen, Yakult, Kyowa Kirin, Ono, Daiichi Sankyo, Chugai, Beigene, Genmab, and LOXO Oncology. TT reports honoraria from MSD, Novartis, Astellas, Kyowa Kirin, SymBio, Nippon Shinyaku, Sumitomo Dainippon, Celgene, Bristol-Myers Squibb, Janssen, and Takeda; research funds from Astellas, AbbVie, CMIC, Kyowa Kirin, Chugai, Nihon Servier, Daiichi Sankyo, Novartis, Nippon Shinyaku, Otsuka, Celgene, Takara Bio, Janssen, and Takeda; and scholarship donations from Chugai, Sanofi, Astellas, Kyowa Kirin, Fuji Pharma, Eisai, Shionogi, Ono, Sumitomo Dainippon, Nippon Shinyaku, Asahi Kasei, Takeda, general incorporated association Kokusai Sentan Iryo Kikoh, and Bristol-Myers Squibb. SS and KY are employees of and report profit of stock from Daiichi Sankyo. KT reports honoraria from Daiichi Sankyo, Celgene, Takeda, HUYA Bioscience, Zenyaku Kogyo, Yakult, Chugai, Mundipharma, Eisai, and Ono. NU reports honoraria from Bristol-Myers Squibb, CMIC, AbbVie, Daiichi Sankyo, IQVIA, Kyowa Kirin, Nippon Shinyaku, Mundipharma, Celgene, Pfizer, Astellas, SymBio, Takeda, Taiho, Zenyaku Kogyo, Solasia, and Meiji Seika. KH reports honoraria from Takeda, Daiichi Sankyo, Towa, Meiji Seika, and Celgene; manuscript fees from Takeda; and scholarship donations from Eisai and Takeda. N. Fukuda, TS, SN, HS, and YK are employees of Daiichi Sankyo.

: This study was performed in compliance with the Declaration of Helsinki, Comprehensive Guidance E6 on Good Clinical Practice, and other applicable requirements and was approved by the independent ethics committees or institutional review boards for all study sites.

: All patients provided written informed consent before enrollment in the study.

: Japan Clinical Trials Information; JapicCTI-183914.

: N/A.

: Data were presented at the 83rd annual meeting of the Japanese Society of Hematology.